Literature DB >> 15998933

ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients.

Julie A Dopheide1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15998933     DOI： 10.2146/ajhp040600

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  4 in total

1.  Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.

Authors:  Amanda Jacques
Journal:  Can Pharm J (Ott)       Date:  2012-09

Review 2.  Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Authors:  Yu-Shu Huang; Ming-Horng Tsai
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 3.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.

Authors:  Rakesh Jain; Thomas Babcock; Teodor Burtea; Bryan Dirks; Ben Adeyi; Brian Scheckner; Robert Lasser; John Renna; Don Duncan
Journal:  Adv Ther       Date:  2013-05-17       Impact factor: 3.845
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.